Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
Open Access
- 1 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 16, 433-441
- https://doi.org/10.2147/copd.s276476
Abstract
Background: Indacaterol/glycopyrronium (IND/GLY) is a once-daily dual bronchodilator for long-term treatment of patients with chronic obstructive pulmonary disease (COPD). The efficacy and safety of IND/GLY have been proved before, but the cost-effectiveness is unknown in China. Purpose: This study assessed cost-effectiveness of IND/GLY comparing with salmeterol/fluticasone (SAL/FLU) and tiotropium. Methods: A patient-level simulation model was established from Chinese payer perspective. Patient parameters were randomly simulated through resampling from parameter distributions based on clinical trials and China-specific cost data to represent individual level health state and health state transitions in the model. We simulated patient-level health state, costs, life years (LYs) and quality-adjusted life years (QALYs) of whole life horizon to evaluate the cost-effectiveness of IND/GLY comparing with SAL/FLU and tiotropium respectively. Results: Comparing with SAL/FLU, IND/GLY resulted in 0.384 LYs and 0.255 QALYs gained. The incremental cost-effectiveness ratio (ICER) is − 35,822 CNY/LY and the incremental cost-utility ratio (ICUR) is − 53,834 CNY/QALY for IND/GLY versus SAL/FLU. Comparing with tiotropium, IND/GLY resulted in 0.232 LYs and 0.146 QALYs gained. The ICER is 39,729 CNY/LY and the ICUR is 63,246 CNY/QALY for IND/GLY versus tiotropium. Conclusion: This study found that dual bronchodilator IND/GLY is cost-effective for stable COPD treatment in China from Chinese payer’s perspective.This publication has 25 references indexed in Scilit:
- Dual bronchodilation with QVA149versussingle bronchodilator therapy: the SHINE studyEuropean Respiratory Journal, 2013
- Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyThe Lancet. Respiratory Medicine, 2013
- COPD in ChinaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2011
- Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPDThe New England Journal of Medicine, 2011
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseThe New England Journal of Medicine, 2008
- The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium BromideAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseThe New England Journal of Medicine, 2007
- Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages?Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Updated Spirometric Reference Values for Adult Chinese in Hong Kong and Implications on Clinical UtilizationSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006